Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors

Inclusion Criteria: * Able to provide written informed consent and commit to recommended EAP assessments. * ≥18 years of age. * Able to swallow tablets. * Histologically confirmed locally advanced, metastatic, and/or unresectable GIST. * Intolerant to imatinib or received prior imatinib therapy for treatment of advanced, metastatic, and/or unresectable GIST that resulted in disease progression. * Meet clinically acceptable local laboratory results. Exclusion Criteria: * Patients who are eligible for and capable of participating in and/or enrolled in an on-going bezuclastinib clinical trial. * Prior or known intolerance to sunitinib. * Patients who have previously participated in a bezuclastinib clinical trial. * Patients with persistent \> Grade 2 toxicities from prior therapy. * Known PDGFR driving mutations or known SDH deficiency. * Pregnant or currently breastfeeding. Other protocol-defined criteria apply.